Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham MedTech & Diagnostics 1x1 Conference virtually on August 13, 2024, hosting one-on-one meetings without a formal presentation. Additionally, Pulse Biosciences management will present at the Canaccord Genuity Annual Growth Conference in Boston on August 14, 2024, at 8:00am ET. A live and recorded webcast of the Canaccord presentation will be available on the company's investor relations website.
Pulse Biosciences (Nasdaq: PLSE), un'azienda specializzata nella tecnologia Nanosecond Pulsed Field Ablation™ (nsPFA™), ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà virtualmente alla 9ª Conferenza Annuale MedTech & Diagnostics 1x1 di Needham il 13 agosto 2024, ospitando incontri uno-a-uno senza una presentazione formale. Inoltre, il management di Pulse Biosciences presenterà alla Conferenza Annuale di Crescita di Canaccord Genuity a Boston il 14 agosto 2024, alle 8:00 ET. Una diretta e una registrazione della presentazione di Canaccord saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda.
Pulse Biosciences (Nasdaq: PLSE), una empresa especializada en la tecnología de Ablación por Campo Pulsado de Nanosegundos™ (nsPFA™), ha anunciado su participación en dos próximas conferencias para inversores. La empresa asistirá virtualmente a la 9ª Conferencia Anual MedTech & Diagnostics 1x1 de Needham el 13 de agosto de 2024, organizando reuniones uno a uno sin una presentación formal. Además, la dirección de Pulse Biosciences presentará en la Conferencia Anual de Crecimiento de Canaccord Genuity en Boston el 14 de agosto de 2024, a las 8:00 a.m. ET. Una transmisión en vivo y grabada de la presentación de Canaccord estará disponible en el sitio web de relaciones con inversionistas de la empresa.
펄스 바이오사이언스(Pulse Biosciences, Nasdaq: PLSE)는 나노초 펄스 필드 절제(nsPFA™) 기술에 특화된 회사로, 두 개의 다가오는 투자자 회의에 참여할 예정이라고 발표했습니다. 이 회사는 제9회 니드햄 메드테크 & 진단 1x1 회의에 가상으로 참석하여 공식 발표 없이 일대일 회의를 진행합니다. 또한, 펄스 바이오사이언스 경영진은 보스턴에서 열리는 카나코드 제뉴인 연례 성장 회의에서 2024년 8월 14일 오전 8시(동부 표준시)에 발표할 예정입니다. 카나코드 발표의 라이브 및 녹화 웹캐스트는 회사의 투자자 관계 웹사이트에서 확인할 수 있습니다.
Pulse Biosciences (Nasdaq: PLSE), une entreprise spécialisée dans la technologie Ablation par Champ Pulsé Nanoseconde™ (nsPFA™), a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise assistera virtuellement à la 9e Conférence Annuelle MedTech & Diagnostics 1x1 de Needham le 13 août 2024, organisant des réunions individuelles sans présentation formelle. De plus, la direction de Pulse Biosciences présentera à la Conférence Annuelle de Croissance de Canaccord Genuity à Boston le 14 août 2024 à 8h00 ET. Une diffusion en direct et enregistrée de la présentation de Canaccord sera disponible sur le site web des relations avec les investisseurs de l'entreprise.
Pulse Biosciences (Nasdaq: PLSE), ein Unternehmen, das auf die Technologie der Nanosogent-Pulsfeld-Ablation™ (nsPFA™) spezialisiert ist, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird virtuell an der 9. Jahrestagung MedTech & Diagnostics 1x1 von Needham am 13. August 2024 teilnehmen und Einzelgespräche ohne formale Präsentation abhalten. Darüber hinaus wird das Management von Pulse Biosciences bei der Jahreswachstumskonferenz von Canaccord Genuity am 14. August 2024 um 8:00 Uhr ET in Boston präsentieren. Eine Live- und aufgezeichnete Übertragung der Canaccord-Präsentation wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
- 9th Annual Needham MedTech & Diagnostics 1x1 Conference, virtual participation. Management will host 1x1 meetings on Tuesday, August 13, 2024. There will be no formal presentation.
-
Canaccord Genuity Annual Growth Conference in
Boston, Massachusetts . Management is scheduled to present on Wednesday, August 14, 2024, at 8:00am ET. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801247190/en/
Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
What investor conferences will Pulse Biosciences (PLSE) attend in August 2024?
When and where will Pulse Biosciences (PLSE) present at the Canaccord Genuity Annual Growth Conference?
Will there be a webcast of Pulse Biosciences' (PLSE) presentation at the Canaccord conference?
What type of meetings will Pulse Biosciences (PLSE) host at the Needham MedTech & Diagnostics Conference?
What is the main technology focus of Pulse Biosciences (PLSE)?
